Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Company can now produce clinical scale phase I, II, III, and small-scale commercial supplies of injectable pharmaceutical products
Subscribe to our email newsletter
OctoPlus has started pharmaceutical production in its new manufacturing facility in Leiden. The facility has received a license from the Dutch authorities to manufacture pharmaceutical products, according to international GMP (Good Manufacturing Practice) guidelines.
The company started to expand the headquarters in November 2006. The new building comprises offices, laboratories and a GMP manufacturing plant that produces final drug product for OctoPlus’ clients.
With the expansion, OctoPlus’ manufacturing capacity more than doubled and the company can now produce clinical scale phase I, II, III, and even small-scale commercial supplies of injectable pharmaceutical products and other complex formulations, said the company.
Simon Sturge, CEO of OctoPlus, said: “We are very proud to report that the expansion of the production facility in our headquarters in Leiden has obtained official approval from the Dutch authorities and we have now started producing pharmaceutical products as a fully licensed facility.”